FOI_8228

Internal Reference Number: FOI_8228

Date Request Received: 23/10/2024 00:00:00

Date Request Replied To: 07/11/2024 00:00:00

This response was sent via: By Email

Request Summary: Chronic lymphocytic leukaemia (CLL)

Request Category: Companies


Question Number 1: How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer To Question 1: 3

Question Number 2: How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment? CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer To Question 2: zero

Question Number 3: Please see attached question and answer sheet.

Answer To Question 3: Please see answer to Q3 attached. To accompany this answer to question 3 please also see the documents listed below: FOI 8228 - Q3 - question and answer sheet (2).pdf
Please see Attachments:


To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.